The significant improvement in outcomes of HER2-positive breast cancer patients achieved with the synergistic use of anti-HER2 drugs with cytotoxic agents in the neoadjuvant setting has prompted the evaluation of various regimens [3–5]. Here, ERBB2 is linked to breast carcinoma.